Videos

The Cleveland Clinic researcher described the 2-fold potential use for how his predictive Parkinson disease dementia model may be used pending the success of the study.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center detailed the promise marked by the results of a recent pilot trial of riluzole in Alzheimer disease.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine detailed the ongoing research in developing gene therapy for patients with Alzheimer disease.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, shared his thoughts on how technology has affected patient care and the patient-physician dynamic during the COVID-19 pandemic.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine detailed the ongoing research in developing gene therapy for patients with Alzheimer disease.

Neurology News Network for the week ending October 17, 2020.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center detailed the findings of a recent pilot trial of riluzole in Alzheimer disease she and colleagues conducted.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why the representation of non-ambulatory patient populations is necessary in DMD trials.

The Cleveland Clinic researcher details a study that will use biomarkers to develop a predictive model to identify individuals with Parkinson disease who may develop dementia.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why turning Duchenne muscular dystrophy into a chronic disease rather than a fatal one, is a top priority.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center discussed the literature that influenced a pilot trial of riluzole in Alzheimer disease.

Episode 2 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and David Lee Gordon, MD, of University of Oklahoma Health Sciences Center. [WATCH TIME: 4 minutes]

Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, discussed whether certain epilepsy populations were affected greater by the COVID-19 pandemic.

Neurology News Network for the week ending October 10, 2020.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided insight on the importance of treating TSC early, and how far away we are from prevention.

The director of Laryngology Research at Mass Eye and Ear spoke to the use of machine learning programs to aid physicians in the diagnosis of dystonia.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, outline how EpiTRAQ may be incorporated in future studies and what outcomes may be observed.

The postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.